Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 6;193(14):E495-E496.
doi: 10.1503/cmaj.202505-f.

Le remdésivir chez les patients atteints de la COVID-19

[Article in French]
Peter E Wu  1 , Andrew M Morris  2
Affiliations

Le remdésivir chez les patients atteints de la COVID-19

[Article in French]
Peter E Wu et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Intérêts concurrents: Peter Wu et Andrew Morris sont respectivement membre et président du groupe de travail ontarien sur l’établissement de guides de pratiques cliniques sur la COVID-19, un groupe de travail provincial bénévole ayant pour but de fournir des guides consensuels fondés sur des données probantes pour le traitement de la COVID-19. Aucun autre intérêt concurrent n’a été déclaré.

References

    1. Beigel JH, Tomashek KM, Dodd LE, et al. ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19: final report. N Engl J Med 2020;383:1813–26. - PMC - PubMed
    1. Wang Y, Zhang D, Du G, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395: 1569–78. - PMC - PubMed
    1. Update on remdesivir: continued monitoring. Ottawa: Health Canada; modified 2020 Nov. 26. Accessible ici : www.canada.ca/en/health-canada/services/drugs-health-products/covid19-in... (consulté le 8 déc. 2020).
    1. Spinner CD, Gottlieb RL, Criner GJ, et al. GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 2020;324: 1048–57. - PMC - PubMed
    1. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo A-M, et al.. Repurposed antiviral drugs for COVID-19: interim WHO Solidarity Trial results. N Engl J Med 2020. Dec. 2 [cyberpublication avant impression]. 10.1056/NEJMoa2023184. - DOI - PMC - PubMed

MeSH terms